Cargando…
Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures
BACKGROUND: Small cell lung cancer (SCLC) is usually diagnosed in the advanced stage. It has a very poor prognosis, with no advancements in therapy in the last few decades. A recent phase 1 clinical study, using an antibody-drug conjugate directed against DLL3, showed promising results. A prerequisi...
Autores principales: | Brcic, Luka, Kuchler, Christian, Eidenhammer, Sylvia, Pabst, Daniela, Quehenberger, Franz, Gazdar, Adi F., Popper, Helmut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528329/ https://www.ncbi.nlm.nih.gov/pubmed/31109352 http://dx.doi.org/10.1186/s13000-019-0827-z |
Ejemplares similares
-
Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated
por: Zacharias, Martin, et al.
Publicado: (2018) -
Senescence and autophagy in usual interstitial pneumonia of different etiology
por: Gallob, Florian, et al.
Publicado: (2020) -
Pleuropulmonary blastoma type I might arise in congenital pulmonary airway malformation type 4 by acquiring a Dicer 1 mutation
por: Brcic, Luka, et al.
Publicado: (2020) -
Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy
por: Popper, Helmut, et al.
Publicado: (2021) -
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
por: Yao, James, et al.
Publicado: (2022)